John N Bonfiglio
Board Member @Sequella, Inc
Denver, CO, US
EMAILS
MOBILE NUMBERS
+19•••••••04
Signup · Get unlimited contacts
WORK HISTORY
Oct 2020 — Present
Board Member @Sequella, Inc
View department →
Rockville, MD, US
Sequella is developing new anti-infectives to treat resistant Tuberculosis and other pathogenic diseases. The company has completed a a Phase 2b study and will be moving to a Phase 3 study or approval in the next 12-18 months. Sequella has several drugs in its pipeline and has received over $70M in government grants to move their development strategies forward.
EDUCATION
1976 — 1980
UC San Diego
PhD, Organic Chemistry
1990 — 1992
Pepperdine University
MBA, Business
1972 — 1976
Stony Brook University
Bachelor of Science (BS), Chemistry
1980 — 1981
University of California, Berkeley
Post doctoral Fellow, organometallic chemistry
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.